The author's reply

New England Journal of Medicine

Volumn 360, Issue 2, 2009, Pages 190-

  Rouse, Dwight J ^a   Hirtz, Deborah G ^b   Thom, Elizabeth A ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; MAGNESIUM SULFATE;

CEREBRAL PALSY; CHILD DEATH; CHORIOAMNIONITIS; CONGENITAL MALFORMATION; DRUG BLOOD LEVEL; GESTATIONAL AGE; HUMAN; LETTER; NEUROPROTECTION; PRIORITY JOURNAL; RACE DIFFERENCE; STILLBIRTH; UMBILICAL CORD BLOOD;

EID: 58249112764     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc082243     Document Type: Letter

References (2)

1. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003;290:2669-76.
2. Marret S, Marpeau L, Follet-Bouhamed C, et al. Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with twoyear neurological outcome: results of the prospective PREMAG trial. Gynecol Obstet Fertil 2008;36:278-88. (In French.)